<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Carbidopa and levodopa: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Carbidopa and levodopa: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Carbidopa and levodopa: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10801" href="/d/html/10801.html" rel="external">see "Carbidopa and levodopa: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F187993"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Dhivy;</li>
<li>Duopa;</li>
<li>Rytary;</li>
<li>Sinemet;</li>
<li>Sinemet CR [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867361"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AA-Levocarb CR;</li>
<li>APO-Levocarb;</li>
<li>APO-Levocarb 100/25;</li>
<li>APO-Levocarb 250/25;</li>
<li>AURO-Levocarb;</li>
<li>Duodopa;</li>
<li>PMS-Levocarb CR [DSC];</li>
<li>Pro-Lecarb;</li>
<li>PRO-Levocarb-100/25 [DSC];</li>
<li>Sinemet 100/25 [DSC];</li>
<li>Sinemet 250/25 [DSC];</li>
<li>TEVA-Levocarbidopa</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F188007"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anti-Parkinson Agent, Decarboxylase Inhibitor;</li>
<li>
                        Anti-Parkinson Agent, Dopamine Precursor</li></ul></div>
<div class="block doa drugH1Div" id="F187997"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="afdbcf58-54a4-4f1f-8310-d12811c549e2">Parkinson disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinson disease: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate-release tablet, orally disintegrating tablet: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Tablets are available in carbidopa 25 mg/levodopa 100 mg, carbidopa 10 mg/levodopa 100 mg, and carbidopa 25 mg/levodopa 250 mg strengths. For patients with daily levodopa requirements ≤400 mg/day, tablets with carbidopa 25 mg/levodopa 100 mg should be used to decrease the risk of adverse effects from peripheral dopamine. For those with higher daily levodopa requirements, different strength tablets may be given to provide the optimum dosage, as long as a carbidopa dose ≥75 mg/day is maintained (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7356419','lexi-content-ref-4082903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7356419','lexi-content-ref-4082903'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: Carbidopa 12.5 mg/levodopa 50 mg or carbidopa 25 mg/levodopa 100 mg 2 to 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9018028','lexi-content-ref-15590952']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9018028','lexi-content-ref-15590952'])">Ref</a></span>); may increase daily dose by 1 tablet of carbidopa 25 mg/levodopa 100 mg every 1 to 2 days. For patients who require higher doses of levodopa for symptom control, titrating with a tablet that has a carbidopa:levodopa ratio of 1:10 may allow for better symptom control without exceeding the usual maximum dosage of carbidopa. Usual maximum daily dose: Carbidopa 200 mg/day and levodopa 2 g/day; dosing frequency ≥4 times daily may be required. <b>Note</b>: Many experts use a slower titration, over weeks to months, to improve tolerability and establish the lowest dose of levodopa that provides a satisfactory clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28243505','lexi-content-ref-Spindler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28243505','lexi-content-ref-Spindler.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Controlled-release tablet: </b>
<b></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note</b>: Intervals between doses should be 4 to 8 hours while awake; when divided doses are not equal, the smaller doses should be given toward the end of the day. <i></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>For patients initiating levodopa therapy: </i>
<b></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Controlled-release carbidopa/levodopa may exhibit erratic pharmacokinetics; therefore, controlled-release formulations are not recommended for initial therapy in Parkinson disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28243505','lexi-content-ref-31501181','lexi-content-ref-Spindler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28243505','lexi-content-ref-31501181','lexi-content-ref-Spindler.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> Initial: Carbidopa 50 mg/levodopa 200 mg 2 times daily, at intervals not &lt;6 hours; may adjust dose no faster than every 3 days to a maximum dose of levodopa 2.4 g/day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Conversion from immediate release to controlled release:</i>
<b>Oral:</b> Initial: Substitute controlled-release dosage at an amount that provides ~10% more levodopa/day; total calculated dosage is administered in divided doses 2 to 3 times/day (or ≥3 times/day for patients maintained on levodopa ≥700 mg). Depending on clinical response, dosage may need to be increased to provide up to 30% more levodopa/day. May adjust dose every 3 days to a maximum dose of levodopa 2.4 g/day. <b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extended-release capsule:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Carbidopa/levodopa ER capsules are not interchangeable with other carbidopa/levodopa products on a 1:1 basis.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>For patients initiating levodopa therapy: </i>
<b>Oral:</b> Initial: Carbidopa 23.75 mg/levodopa 95 mg 3 times daily for 3 days; on day 4, may increase to carbidopa 36.25 mg/levodopa 145 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28243505','lexi-content-ref-24055014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28243505','lexi-content-ref-24055014'])">Ref</a></span>). May increase dose further based on response and tolerability in levodopa 50 mg increments at intervals ≥1 week up to carbidopa 97.5 mg/levodopa 390 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28243505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28243505'])">Ref</a></span>). Frequency of dosing may be increased to a maximum of 5 times daily if needed and tolerated (maximum: carbidopa 612.5 mg/levodopa 2.45 g per day).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Conversion from immediate release to extended release</i>: <b>Oral: </b>Initial: Dose based on current total daily dose of levodopa in immediate-release carbidopa/levodopa as follows:</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Conversion From Immediate-release to Extended-release Carbidopa/Levodopa (Capsules)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Total daily dose of levodopa in immediate-release carbidopa/levodopa</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Recommended starting dosage of extended-release carbidopa/levodopa<sup class="footnote-number">a</sup></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">Total daily dose of levodopa in extended-release carbidopa/levodopa</p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Initial extended</b>-release<b> carbidopa/levodopa dosing regimen</b>
<sup class="footnote-number">b</sup></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<b>
<sup>a</sup></b>For patients currently treated with IR carbidopa/levodopa <b>plus</b> catechol-O-methyl transferase (COMT) inhibitors (eg, entacapone) and converting to monotherapy with carbidopa/levodopa ER capsules, the initial total daily dose of carbidopa/levodopa ER capsules may need to be increased.</p>
<p style="text-indent:0em;text-align:left;">
<sup>b</sup>Adjust dose as needed; frequency of dosing may be increased to a maximum of 5 times daily if needed and tolerated (maximum dose: carbidopa 612.5 mg/levodopa 2.45 g per day) (Espay 2017).</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">400 to 549 mg</p></td>
<td align="center">
<p style="text-indent:0em;">855 mg</p></td>
<td align="center">
<p style="text-indent:0em;">3 capsules ER carbidopa 23.75 mg/levodopa 95 mg 3 times daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">550 to 749 mg</p></td>
<td align="center">
<p style="text-indent:0em;">1.14 g</p></td>
<td align="center">
<p style="text-indent:0em;">4 capsules ER carbidopa 23.75 mg/levodopa 95 mg 3 times daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">750 to 949 mg</p></td>
<td align="center">
<p style="text-indent:0em;">1.305 g</p></td>
<td align="center">
<p style="text-indent:0em;">3 capsules ER carbidopa 36.25 mg/levodopa 145 mg 3 times daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">950 mg to 1.249 g</p></td>
<td align="center">
<p style="text-indent:0em;">1.755 g</p></td>
<td align="center">
<p style="text-indent:0em;">3 capsules ER carbidopa 48.75 mg/levodopa 195 mg 3 times daily</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">≥1.25 g</p></td>
<td align="center">
<p style="text-indent:0em;">2.205 g</p></td>
<td align="center">
<p style="text-indent:0em;">3 capsules ER carbidopa 61.25 mg/levodopa 245 mg 3 times daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>or </b></p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">2.34 g</p></td>
<td align="center">
<p style="text-indent:0em;">4 capsules ER carbidopa 48.75 mg/levodopa 195 mg 3 times daily</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intestinal suspension (Duopa), intestinal gel (Duodopa [Canadian product]):</b>
<b></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Prior to initiation of therapy, convert patients from all forms of levodopa to oral IR carbidopa/levodopa tablets. Total daily dose of intestinal infusion (expressed in terms of levodopa) consists of a morning dose, a continuous dose, and extra doses. Maximum daily dose is levodopa 2 g (ie, one cassette per day) administered over 16 hours. Following the daily 16-hour infusion, some patients may require a routine nighttime dosage of oral carbidopa/levodopa. Nighttime intestinal infusion dosing may be necessary in certain rare situations (eg, nocturnal akinesia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26946221']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26946221'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Intestinal infusion via PEG-J tube: Initial: <b>
<i></i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Morning bolus dose:</i></b>
<i>Day 1:</i> Determine levodopa dose by using previous day's <b>first</b> oral IR carbidopa/levodopa dose. Reduce this dose to 60% to 80% of first oral IR carbidopa/levodopa dose and administer this amount over 10 to 30 minutes; usual levodopa dose: 100 to 200 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30363427','lexi-content-ref-23287001','lexi-content-ref-25962554','lexi-content-ref-24361112','lexi-content-ref-24055014','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30363427','lexi-content-ref-23287001','lexi-content-ref-25962554','lexi-content-ref-24361112','lexi-content-ref-24055014','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Continuous dose:</i></b>
<i>Day 1:</i> Determine the amount of oral IR levodopa received in previous day's <b>total </b>waking hours. Do not include nighttime or first oral IR carbidopa/levodopa doses. Divide by 16 hours (usual duration of infusion) for hourly infusion rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30363427','lexi-content-ref-24361112','lexi-content-ref-24055014','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30363427','lexi-content-ref-24361112','lexi-content-ref-24055014','lexi-content-ref-manu.1'])">Ref</a></span>). Usual levodopa dose: 20 to 120 mg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25962554','lexi-content-ref-12782919']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25962554','lexi-content-ref-12782919'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Extra bolus doses:</i></b> Usual levodopa dose: 10 to 40 mg every 1 to 2 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25962554','lexi-content-ref-24055014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25962554','lexi-content-ref-24055014'])">Ref</a></span>). <b>Note:</b> Frequent extra doses may cause or worsen dyskinesias. <b></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Day 2 and subsequent dosage adjustment:</b> After day 1 of intestinal infusion, adjust as needed based on response and tolerability.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="be43cdd3-ce21-4fc1-aab2-7b1bf1338876">Restless legs syndrome, intermittent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Restless legs syndrome, intermittent (alternative agent) (off-label use)</b>:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>: Due to risk of augmentation (worsening symptoms during dopaminergic therapy), limit frequency to 2 to 3 administrations per week. May also be taken as needed prior to specific restless legs syndrome (RLS) triggers, such as prolonged immobility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27448465']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27448465'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate-release tablet: Oral:</b> Initial: Carbidopa 12.5 mg/levodopa 50 mg to carbidopa 25 mg/levodopa 100 mg as needed in the evening, at bedtime, or upon waking during the night due to RLS symptoms; may adjust dose (based on levodopa component) no faster than every 3 days to a maximum of 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9085489','lexi-content-ref-22937989','lexi-content-ref-15244390']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9085489','lexi-content-ref-22937989','lexi-content-ref-15244390'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Controlled-release tablet:</b>
<b>Oral:</b> Initial: Carbidopa 25 mg/levodopa 100 mg as needed before bedtime for RLS symptoms that awaken patient during the night; may adjust dose (based on levodopa component) no faster than every 3 days to a maximum dose of 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9085489','lexi-content-ref-22937989','lexi-content-ref-15244390']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9085489','lexi-content-ref-22937989','lexi-content-ref-15244390'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Discontinuation of therapy</i></b>: Discontinuation of therapy may result in neuroleptic malignant-like syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31501181','lexi-content-ref-12573874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31501181','lexi-content-ref-12573874'])">Ref</a></span>). Avoid sudden discontinuation or rapid dose reduction; some experts recommend a gradual taper over several weeks or more (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Oliver.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Oliver.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990905"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Carbidopa has low pharmacologic activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-lodosyn.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-lodosyn.2020'])">Ref</a></span>); recommendations below focus on levodopa component.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b>No dosage adjustment likely to be necessary for any degree of kidney impairment (levodopa renal clearance in the presence of carbidopa is ~10% of total clearance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2685649','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2685649','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly): </b>Levodopa unlikely to be significantly dialyzable (moderate V<sub>d</sub>, rapid metabolism): No dose adjustment likely to be necessary. When scheduled doses fall during hemodialysis, administer at least one hour before hemodialysis or after the hemodialysis session has been completed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis: </b>Levodopa unlikely to be significantly dialyzable (moderate V<sub>d</sub>, rapid metabolism): No dose adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Levodopa unlikely to be significantly dialyzable (moderate V<sub>d</sub>, rapid metabolism): No dose adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Levodopa unlikely to be significantly dialyzable (moderate V<sub>d</sub>, rapid metabolism): No dose adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988176"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p></div>
<div class="block dot drugH1Div" id="F27102717"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">Intestinal suspension (Duopa):</p>
<p style="text-indent:-2em;margin-left:2em;">Dyskinesias or levodopa-related adverse reactions within 1 hour of morning dose on preceding day: Decrease morning levodopa dose by 20 mg.</p>
<p style="text-indent:-2em;margin-left:2em;">Dyskinesias or adverse reactions lasting ≥1 hour on the preceding day: Decrease continuous levodopa dose by 6 mg per hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Dyskinesias or adverse reactions lasting for 2 or more periods of ≥1 hour on the preceding day: Decrease continuous levodopa dose by 12 mg per hour.</p></div>
<div class="block doe drugH1Div" id="F187998"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F55173003"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Dyskinesia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Carbidopa and levodopa may cause or exacerbate<b> dyskinesia. </b>Peak-dose dyskinesia typically occurs (during maximal plasma concentrations), but diphasic dyskinesia may also occur (beginning and end of a dose cycle). Off-period dystonia may also occur; commonly affects the foot and can be painful. Off-period dystonia tends to occur early in the day, precipitated by anxiety or attempts to walk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23948989']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23948989'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; appears to involve multiple neuronal pathways and neurotransmitter systems. The primary mechanism involves intermittent or pulsatile stimulation of striatal dopamine (D1) receptors linked to intermittent levodopa delivery to the brain. Off-period dystonia results from low levodopa concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31619083']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31619083'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; may occur early or later with chronic levodopa use. Peak-dose dyskinesias occur early. Off-period dystonia occurs after months or years of chronic levodopa use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23948989']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23948989'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher levodopa doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31619083','lexi-content-ref-28229895']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31619083','lexi-content-ref-28229895'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Long treatment duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28229895']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28229895'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Anxious-depressed subtype (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31619083','lexi-content-ref-28229895']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31619083','lexi-content-ref-28229895'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Asymmetry of caudate binding on DaTscan (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31619083']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31619083'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31619083','lexi-content-ref-28229895']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31619083','lexi-content-ref-28229895'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Low bodyweight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31619083','lexi-content-ref-28229895']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31619083','lexi-content-ref-28229895'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Motor fluctuations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31619083']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31619083'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Non-smoker (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31619083']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31619083'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Non-tremor dominant phenotype (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31619083']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31619083'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Young age at onset of Parkinson disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31619083','lexi-content-ref-28229895']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31619083','lexi-content-ref-28229895'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea</b> and <b>vomiting</b> are frequently reported in Parkinson disease patients taking carbidopa and levodopa; however, the incidence of nausea and vomiting with carbidopa and levodopa is lower than with levodopa alone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4834974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4834974'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: May be dose-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4834974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4834974'])">Ref</a></span>); attributed to dopamine in peripheral tissues. Peripheral levodopa decarboxylation is inhibited by carbidopa, contributing to less nausea and vomiting than with levodopa alone.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied (based on data from individual components); may occur with the first dose, high doses, or with dose increases of levodopa (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4834974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4834974'])">Ref</a></span>) and may occur with doses of carbidopa ≤70 to 100 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4834974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4834974'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4834974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4834974'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dose increases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4834974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4834974'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Impulse control disorders</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Dopaminergic medications have been associated with <b>impulse control disorder</b>, including <b>pathological gambling</b>, compulsive shopping, binge eating disorder, punding, and compulsive sexual behavior (<b>increased libido</b> [including hypersexuality]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19339647','lexi-content-ref-32761061','lexi-content-ref-28229895','lexi-content-ref-25370355']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19339647','lexi-content-ref-32761061','lexi-content-ref-28229895','lexi-content-ref-25370355'])">Ref</a></span>). Most reports have occurred with dopamine agonist therapy (eg, pramipexole, ropinirole) concurrently with carbidopa/levodopa. Risk with carbidopa/levodopa monotherapy is low (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19339647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19339647'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: In susceptible individuals with a hypersensitivity to rewards, impulse control disorders may develop with dopamine replacement therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32761061','lexi-content-ref-28229895']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32761061','lexi-content-ref-28229895'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; in case reports, onset ranged from months to years after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19339647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19339647'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Young age at the onset of Parkinson disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25370355']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25370355'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Greater use of caffeine and cigarettes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28229895']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28229895'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High novelty seeking and impulsivity personality traits (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28229895']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28229895'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Motor complications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25370355']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25370355'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Personal or family history of alcohol or substance use disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25370355']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25370355'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Personal or family history of gambling (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28229895','lexi-content-ref-25370355']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28229895','lexi-content-ref-25370355'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (compulsive shopping and eating) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25370355']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25370355'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (hypersexuality) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25370355']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25370355'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Orthostatic hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Orthostatic hypotension </b>may occur with carbidopa and levodopa. Neurogenic orthostatic hypotension may occur independently with the pathophysiology of Parkinson disease; dopaminergic medications may contribute (non-neurogenic). Levodopa may contribute less than other dopaminergic medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31427383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31427383'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; may be related to the baroreflex dysfunction caused by levodopa (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15556835']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15556835'])">Ref</a></span>). A direct dopamine agonist effect by levodopa may also play a role (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11030798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11030798'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">General:</p>
<p style="text-indent:-2em;margin-left:8em;">• Cardiac dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31427383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31427383'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Combined therapies (eg, dopamine agonists, monoamine oxidase inhibitors [MAOIs]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31427383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31427383'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent medications that may decrease blood pressure (eg, alpha-blockers, antihypertensives, diuretics, sildenafil) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11030798','lexi-content-ref-31427383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11030798','lexi-content-ref-31427383'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31427383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31427383'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Drug-related:</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11030798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11030798'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Peripheral neuropathy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral neuropathy</b> may occur with carbidopa and levodopa (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30838307']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30838307'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Exact mechanism unclear; may be related to the metabolic pathway of levodopa, resulting in the accumulation of neurotoxins such as homocysteine (Hcy) and methylmalonic acid (MMA) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30838307']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30838307'])">Ref</a></span>). Immune-mediated inflammatory mechanisms, possibly triggered by the PEG-J tube or by the gel formulation, may also play a role (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30838307']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30838307'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; most cases are delayed but some intestinal gel cases are acute or subacute onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30838307']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30838307'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic exposure to levodopa (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30838307']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30838307'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Genetic factors (eg, quantitative or functional deficiency of 5,10-methylenetetrahydrofolate reductase (MTHFR) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30838307']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30838307'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30838307']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30838307'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Psychiatric behavior abnormalities</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Psychiatric behavior abnormalities such as <b>agitation</b>, <b>confusion</b>,<b> delirium</b>, <b>delusion</b>, <b>disorientation</b>, <b>hallucination</b> (visual and/or auditory), <b>paranoid ideation</b>, and <b>psychosis</b> may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8750001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8750001'])">Ref</a></span>). These behaviors are generally reversible with dose adjustment; discontinuation rarely required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-5000569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-5000569'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; may induce hypersensitivity of limbic dopamine receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25491470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25491470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; may progress over weeks to months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9143857']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9143857'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses of levodopa (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23948989','lexi-content-ref-9143857']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23948989','lexi-content-ref-9143857'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of a major psychotic disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23948989','lexi-content-ref-9143857']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23948989','lexi-content-ref-9143857'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults with prior history of dementia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9143857']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9143857'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger patients (mania) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25491470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25491470'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal syndrome/Parkinsonism-hyperpyrexia syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Withdrawal syndrome, also known as Parkinsonism-hyperpyrexia syndrome (PHS), is a rare but potentially fatal condition in patients with Parkinson disease (PD) and is manifested by pyrexia, muscle rigidity, a reduced level of consciousness, and autonomic instability. It is generally believed that rapid withdrawal of antiparkinsonian drugs or abrupt changes in medication regimens is the primary cause of this syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18712508','lexi-content-ref-31427383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18712508','lexi-content-ref-31427383'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Withdrawal; most likely sudden suppression of central dopaminergic activity. May also include changes in peripheral and central sympathetic outflow and alteration in central serotonin metabolism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18712508','lexi-content-ref-31427383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18712508','lexi-content-ref-31427383'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; typically within 18 hours to 7 days following trigger (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18712508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18712508'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Altered absorption/bioavailability of levodopa (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31427383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31427383'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent antipsychotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18712508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18712508'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dehydration and excessively hot weather (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20404676','lexi-content-ref-18712508','lexi-content-ref-31427383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20404676','lexi-content-ref-18712508','lexi-content-ref-31427383'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Physiological stressors (eg, infection, injury, surgery, trauma) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31427383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31427383'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid withdrawal of levodopa (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20404676','lexi-content-ref-18712508','lexi-content-ref-31427383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20404676','lexi-content-ref-18712508','lexi-content-ref-31427383'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F187965"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Orthostatic hypotension (enteral suspension: 70% to 73%; oral: 1% to 68%)<span class="lexi-table-link-container"> (<a aria-label="Orthostatic Hypotension table link" class="lexi-table-link" data-table-id="lexi-content-orthostatic-hypotension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-orthostatic-hypotension')">table 1</a>)</span><span class="table-link" style="display:none;">Orthostatic Hypotension</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Orthostatic Hypotension" frame="border" id="lexi-content-orthostatic-hypotension" rules="all">
<caption style="text-align:center;">
<b>Carbidopa and Levodopa: Adverse Reaction: Orthostatic Hypotension</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Carbidopa and Levodopa)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Carbidopa and Levodopa)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">73%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Enteral suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Advanced Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">37</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Orthostatic systolic hypotension (≥30 mm Hg decrease)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">70%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Enteral suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Advanced Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">37</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Orthostatic diastolic hypotension (≥20 mm Hg decrease)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">68%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Advanced Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">34</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Orthostatic systolic hypotension (≥30 mm Hg decrease)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">62%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Advanced Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">34</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Orthostatic diastolic hypotension (≥20 mm Hg decrease)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">97.5 mg carbidopa/390 mg levodopa 3 times daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">92</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">36.25 mg carbidopa/145 mg levodopa 3 times daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">92</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">61.25 mg carbidopa/245 mg levodopa 3 times daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">104</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">92</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Controlled-release tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">491</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">524</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (enteral suspension: 22%; oral: ≤6%), nausea (enteral suspension: 30%; oral: 2% to 21%)<span class="lexi-table-link-container"> (<a aria-label="Nausea table link" class="lexi-table-link" data-table-id="lexi-content-nausea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nausea')">table 2</a>)</span><span class="table-link" style="display:none;">Nausea</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Nausea" frame="border" id="lexi-content-nausea" rules="all">
<caption style="text-align:center;">
<b>Carbidopa and Levodopa: Adverse Reaction: Nausea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Carbidopa and Levodopa)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Carbidopa and Levodopa)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">30%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Enteral suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Advanced Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">37</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Advanced Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">34</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Advanced Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">201</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Advanced Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">192</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">97.5 mg carbidopa/390 mg levodopa 3 times daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">92</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">61.25 mg carbidopa/245 mg levodopa 3 times daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">104</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">92</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">36.25 mg carbidopa/145 mg levodopa 3 times daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">92</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Controlled-release tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">491</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">524</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (enteral suspension: 11%; oral: 1% to 2%), dizziness (2% to 19%), headache (oral: 1% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dyskinesia (2% to 17%)<span class="lexi-table-link-container"> (<a aria-label="Dyskinesia table link" class="lexi-table-link" data-table-id="lexi-content-dyskinesia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dyskinesia')">table 3</a>)</span><span class="table-link" style="display:none;">Dyskinesia</span>, increased creatine phosphokinase in blood specimen (enteral suspension: ≤17%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dyskinesia" frame="border" id="lexi-content-dyskinesia" rules="all">
<caption style="text-align:center;">
<b>Carbidopa and Levodopa: Adverse Reaction: Dyskinesia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Carbidopa and Levodopa)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Carbidopa and Levodopa)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Enteral suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Advanced Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">37</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Advanced Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">34</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">97.5 mg carbidopa/390 mg levodopa 3 times daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">92</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">61.25 mg carbidopa/245 mg levodopa 3 times daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">104</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">92</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">36.25 mg carbidopa/145 mg levodopa 3 times daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">92</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Controlled-release tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">491</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">524</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen (enteral suspension: ≤13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (oral: ≤1%), hypertension (enteral suspension: 8%), ischemia (oral: ≤2%), peripheral edema (enteral suspension: 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (enteral suspension: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum glucose (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (oral: 1%), diarrhea (≤5%), dyspepsia (≤5%), vomiting (oral: 2% to 5%)<span class="lexi-table-link-container"> (<a aria-label="Vomiting table link" class="lexi-table-link" data-table-id="lexi-content-vomiting" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-vomiting')">table 4</a>)</span><span class="table-link" style="display:none;">Vomiting</span>, xerostomia (oral: 1% to 7%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Vomiting" frame="border" id="lexi-content-vomiting" rules="all">
<caption style="text-align:center;">
<b>Carbidopa and Levodopa: Adverse Reaction: Vomiting</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Carbidopa and Levodopa)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Carbidopa and Levodopa)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">97.5 mg carbidopa/390 mg levodopa 3 times daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">92</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">36.25 mg carbidopa/145 mg levodopa 3 times daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">92</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">61.25 mg carbidopa/245 mg levodopa 3 times daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">104</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">92</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Controlled-release tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">491</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe Parkinson disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">524</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Bacteriuria (enteral suspension: 5%; oral: ≥1%), hematuria (oral: ≥1%), urinary frequency (oral: ≤1%), urinary tract infection (oral: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hematocrit (oral: ≥1%), decreased hemoglobin (oral: ≥1%), leukocyturia (enteral suspension: 5%; oral: ≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (oral: ≤6%), anxiety (2% to 8%), confusion (2% to 8%), hallucination (≤5%, visual and/or auditory) (Spieker 1995), insomnia (oral: 1% to 9%), on-off phenomenon (oral: 1% to 2%), paresthesia (oral: ≤1%), polyneuropathy (enteral suspension: 5%), psychosis (≤5%), sleep disorder (enteral suspension: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (oral: ≤2%), dystonia (oral: ≤2%), muscle cramps (oral: ≤1%), shoulder pain (oral: ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Atelectasis (enteral suspension: 8%), dyspnea (oral: ≤2%), oropharyngeal pain (enteral suspension: 8%), upper respiratory tract infection (enteral suspension: 8%; oral: 1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (enteral suspension: 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Hematologic &amp; oncologic: Malignant melanoma (causation not established; melanoma more common in Parkinson disease than the general population) (Bertoni 2010)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (Ng 2019), cardiac arrhythmia (Simsek 2005), phlebitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (Marshall 1971), bullous rash (including pemphigus-like reactions) (Forschner 2005), diaphoresis, discoloration of sweat, urticaria (Anang 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash, hyponatremia (Shihabudheen 2020), increased libido (including hypersexuality) (Bostwick 2009), pyridoxine deficiency (Wise 2022), weight gain, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, bruxism, discoloration of saliva, duodenal ulcer, dysgeusia, dysphagia, flatulence, gastrointestinal hemorrhage, heartburn, hiccups (Shihabudheen 2020), sialorrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Glycosuria, priapism, proteinuria, urinary incontinence, urinary retention, urine discoloration</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, anemia, hemolytic anemia (Linström 1977), Henoch-Schonlein purpura (Niedermaier 1997), leukopenia (Cordano 2015), positive direct Coombs' test (Joseph 1972), thrombocytopenia (Lee 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate transaminase, increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal behavior, abnormal gait, abnormality in thinking, agitation, asthenia, ataxia, decreased mental acuity, delirium, delusion (Spieker 1995), dementia, disorientation, drowsiness, euphoria, extrapyramidal reaction, falling, fatigue, glossopyrosis, Horner’s syndrome, impulse control disorder (Bostwick 2009), malaise, memory impairment, narcolepsy, nervousness, neuroleptic malignant syndrome (Perry 2012), nightmares, numbness, paranoid ideation (Spieker 1995), pathological gambling (Bostwick 2009), peripheral neuropathy, seizure, sense of stimulation, suicidal ideation (Ayobello 2019), suicidal tendencies (Ayobello 2019), trismus, withdrawal syndrome (Parkinsonism-hyperpyrexia syndrome) (Newman 2009, Simonet 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lower extremity pain</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharospasm (Ramirez-Gomez 2019), blurred vision, diplopia, mydriasis, oculogyric crisis (Kondo 1995)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, hoarseness</p></div>
<div class="block coi drugH1Div" id="F187981"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to levodopa, carbidopa, or any component of the formulation; concurrent use with nonselective monoamine oxidase inhibitors (MAOIs) or use within the last 14 days</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Additional contraindications: Narrow angle glaucoma</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Clinical or laboratory evidence of uncompensated cardiovascular, endocrine, hepatic, hematologic or pulmonary disease (eg, including bronchial asthma), or renal disease; concomitant administration of a sympathomimetic amine (eg, epinephrine, norepinephrine, isoproterenol); in the presence of a suspicious, undiagnosed skin lesion or history of melanoma; intestinal gel therapy in patients with any condition preventing the required placement of a PEG tube for administration (ie, pathological changes of gastric wall, inability to bring gastric and abdominal wall together, blood coagulation disorders, peritonitis, acute pancreatitis, paralytic ileus).</p></div>
<div class="block war drugH1Div" id="F187962"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Somnolence: Somnolence and falling asleep while engaged in activities of daily living (including operation of motor vehicles) have been reported; some cases reported that there were no warning signs for the onset of symptoms. Symptom onset may occur well after initiation of treatment; some events have occurred more than 1 year after start of therapy. Prior to treatment initiation, evaluate for factors that may increase these risks such as concomitant sedating medications, and the presence of sleep disorders. Monitor for drowsiness or sleepiness. If significant daytime sleepiness or episodes of falling asleep during activities that require active participation occurs (eg, driving, conversations, eating), discontinue the medication. There is insufficient information to suggest that dose reductions will eliminate these symptoms. If therapy is continued, advise patient to avoid driving and other potentially dangerous activities.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with severe cardiovascular disease, including a history of myocardial infarction who have residual atrial, nodal, or ventricular arrhythmias.</p>
<p style="text-indent:-2em;margin-left:4em;">• Endocrine disease: Use with caution in patients with endocrine disease and when interpreting plasma/urine catecholamine levels; falsely diagnosed pheochromocytoma has been rarely reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: Use with caution in patients with glaucoma; monitor IOP carefully; some formulations are contraindicated in patients with narrow-angle glaucoma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peptic ulcer disease: Oral products: Use with caution in patients with a history of peptic ulcer disease; risk of GI hemorrhage may be increased.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use with caution in patients with respiratory disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in elderly patients; may be more sensitive to CNS effects (eg, hallucinations) of levodopa.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage forms specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Intestinal suspension (Duopa): GI complications (eg, bezoar, ileus, implant-site erosion/ulcer, intestinal hemorrhage, intestinal ischemia, intestinal obstruction, intestinal perforation, pancreatitis, peritonitis, pneumoperitoneum, postoperative wound infection) may occur (may be fatal). Patients should notify their health care provider immediately if abdominal pain, prolonged constipation, nausea, vomiting, fever, and/or melanotic stool occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intestinal gel (Duodopa [Canadian product]): Product should be prescribed only by neurologists experienced in the treatment of Parkinson disease and who have completed the Duodopa Education Program. Response to levodopa/carbidopa intestinal gel therapy should be assessed with a short-term test period of administration via a temporary nasojejunal tube prior to placement of a percutaneous endoscopic gastrostomy-jejunostomy (PEG-J) tube for permanent access and administration. Sudden deterioration in therapy response with recurring motor symptoms may indicate PEG-J tube complications (eg, displacement) or obstruction of the infusion device. Tube or infusion device complications may require initiation of oral levodopa/carbidopa therapy until complications are resolved.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Body fluid discoloration: Urine, saliva, or sweat may appear dark in color (red, brown, black) during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dietary protein: Distribute dietary protein throughout the day to avoid fluctuations in levodopa absorption. A high-protein diet may reduce the effectiveness of the enteral formulations.</p></div>
<div class="block foc drugH1Div" id="F187974"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rytary: Carbidopa 23.75 mg and levodopa 95 mg, Carbidopa 36.25 mg and levodopa 145 mg, Carbidopa 48.75 mg and levodopa 195 mg, Carbidopa 61.25 mg and levodopa 245 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Enteral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Duopa: Carbidopa 5 mg and levodopa 20 mg per mL (100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dhivy: Carbidopa 25 mg and levodopa 100 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sinemet: Carbidopa 10 mg and levodopa 100 mg [scored; contains corn starch, fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sinemet: Carbidopa 25 mg and levodopa 100 mg [scored; contains corn starch, quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sinemet: Carbidopa 10 mg and levodopa 100 mg [DSC], Carbidopa 25 mg and levodopa 250 mg [DSC] [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sinemet: Carbidopa 25 mg and levodopa 100 mg [DSC] [contains quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Carbidopa 10 mg and levodopa 100 mg, Carbidopa 25 mg and levodopa 100 mg, Carbidopa 25 mg and levodopa 250 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Carbidopa 10 mg and levodopa 100 mg, Carbidopa 25 mg and levodopa 100 mg, Carbidopa 25 mg and levodopa 250 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sinemet CR: Carbidopa 25 mg and levodopa 100 mg [DSC] [contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Carbidopa 25 mg and levodopa 100 mg, Carbidopa 50 mg and levodopa 200 mg</p></div>
<div class="block geq drugH1Div" id="F187958"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F187984"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule Extended Release</b> (Rytary Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">23.75-95 mg (per each): $4.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">36.25-145 mg (per each): $4.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">48.75-195 mg (per each): $4.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">61.25-245 mg (per each): $6.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Duopa Enteral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4.63-20 mg/mL (per mL): $2.71</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Carbidopa-Levodopa ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25-100 mg (per each): $0.94 - $0.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50-200 mg (per each): $1.81 - $1.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (Carbidopa-Levodopa Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10-100 mg (per each): $1.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25-100 mg (per each): $1.38</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25-250 mg (per each): $1.75</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Carbidopa-Levodopa Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10-100 mg (per each): $0.71 - $0.77</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25-100 mg (per each): $0.23 - $1.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25-250 mg (per each): $0.95 - $1.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Dhivy Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25-100 mg (per each): $3.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Sinemet Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10-100 mg (per each): $1.43</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25-100 mg (per each): $1.61</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867362"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, Enteral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Duodopa: Carbidopa 5 mg and levodopa 20 mg per mL (100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sinemet 250/25: Carbidopa 25 mg and levodopa 250 mg [DSC] [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sinemet 100/25: Carbidopa 25 mg and levodopa 100 mg [DSC] [contains fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Carbidopa 10 mg and levodopa 100 mg, Carbidopa 25 mg and levodopa 100 mg, Carbidopa 25 mg and levodopa 250 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Carbidopa 25 mg and levodopa 100 mg, Carbidopa 50 mg and levodopa 200 mg</p></div>
<div class="block accres drugH1Div" id="F11236626"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;margin-left:0em;display:inline">
<b>Duodopa intestinal gel [Canadian product]:</b> In Canada, the Duodopa Education Program is a risk mitigation program established to provide safe and effective use of Duodopa in advanced Parkinson patients. The program involves:</p>
<p style="text-indent:-2em;margin-left:2em;">- Education of prescribing neurologists and other health care providers on suitable candidates for treatment, surgical procedures (PEG tube placement), and follow-up care including infusion device education.</p>
<p style="text-indent:-2em;margin-left:2em;">- Distribution of educational materials to patients and caregivers describing Duodopa intestinal gel and its proper use, PEG tube placement, and complications associated with the mode of administration and/or PEG tube placement.</p></div>
<div class="block adm drugH1Div" id="F187978"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intestinal suspension (Duopa):</b> Remove one cassette from refrigerator 20 minutes prior to use (failure to use at room temperature may result in inaccurate dosage). Administer as a 16-hour infusion through either a nasojejunal tube (temporary administration) or through a percutaneous endoscopic gastrostomy-jejunostomy (PEG-J) tube (long-term administration) connected to the CADD-Legacy 1400 pump. At the end of administration, disconnect the tube from the pump at the end of the infusion and flush with room-temperature drinking water with a syringe. Following discontinuation of the daily infusion, patients should administer their routine night-time dosage of oral immediate-release carbidopa/levodopa.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intestinal gel (Duodopa [Canadian product]):</b> Gel is administered directly to the jejunum via a portable infusion pump (CADD-legacy Duodopa pump). Administer through a temporary nasojejunal tube for a short-term test period to evaluate patient response and for dose optimization. Long-term administration requires placement of PEG-J tube for intestinal infusion. Continuous maintenance dose is infused throughout the day for up to 16 hours; if necessary, may administer at night (eg, nocturnal akinesia). Disconnect PEG-J tube from infusion pump at end of infusion and flush with room temperature water to prevent occlusion of tubing. Following discontinuation of the daily infusion, patients should administer their routine night-time dosage of oral levodopa/carbidopa.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Extended-release capsule: Administer with or without food; a high-fat, high-calorie meal may delay the absorption of levodopa by ~2 hours. Swallow capsules whole; do not chew, divide, or crush capsules. Patients who have difficulty swallowing intact capsules may open the capsule, sprinkle entire contents on a small amount of applesauce (1 to 2 tablespoons) and consume immediately (do not store for future use).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral tablet formulations: Space doses evenly over the waking hours. Administer with meals to decrease GI upset. Controlled release product should not be chewed or crushed. Orally disintegrating tablets do not require water; the tablet should disintegrate on the tongue's surface before swallowing.</p>
<p style="text-indent:-2em;margin-left:6em;">Dhivy: Administer without regard to food; tablets may be broken at score lines if patient has difficulty swallowing large tablets.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Capsule and tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Do not cut, crush, or chew. Switch to immediate-release formulation (tablet or orally disintegrating tablet) or capsule may be opened and contents sprinkled onto soft food of choice. Patient should be instructed to swallow the mixture without biting down or chewing.</p></div>
<div class="block use drugH1Div" id="F187977"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Parkinson disease:</b> Treatment of Parkinson disease, postencephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide and/or manganese intoxication; treatment of motor fluctuations in advanced Parkinson disease (intestinal suspension [Duopa] only).</p></div>
<div class="block off-label drugH1Div" id="F25722063"><span class="drugH1">Use: Off-Label: Adult</span><p>Parkinsonism (including corticobasal degeneration, dementia with Lewy bodies, drug-induced parkinsonism, multiple system atrophy, and progressive supranuclear palsy); Restless legs syndrome, intermittent</p></div>
<div class="block mst drugH1Div" id="F6842204"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Sinemet may be confused with Janumet, Serevent</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Zimox: Brand name for carbidopa and levodopa [Greece], but also the brand name for amoxicillin [Italy]</p>
<p style="text-indent:-2em;margin-left:4em;">Zimox [Greece] may be confused with Diamox which is a brand name for acetazolamide [Canada and multiple international markets]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298971"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F187967"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Injection): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Amisulpride (Oral). Amisulpride (Oral) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (First Generation [Typical]): Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotic Agents (First Generation [Typical]). Antipsychotic Agents (First Generation [Typical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).  Management: Avoid concomitant therapy if possible. If antipsychotic use is necessary, consider using atypical antipsychotics such as clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Management: Consider avoiding atypical antipsychotic use in patients with Parkinson disease. If an atypical antipsychotic is necessary, consider using clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Biperiden: May enhance the adverse/toxic effect of Levodopa-Foslevodopa. Specifically, the risk of choreic movements or dyskinesias may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Levodopa-Foslevodopa.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist). Specifically, the risk of chorea may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: Anti-Parkinson Agents (Dopamine Agonist) may enhance the adverse/toxic effect of BuPROPion. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Droxidopa: Carbidopa may diminish the therapeutic effect of Droxidopa. Carbidopa may decrease serum concentrations of the active metabolite(s) of Droxidopa. Carbidopa may increase the serum concentration of Droxidopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: May diminish the therapeutic effect of Levodopa-Foslevodopa.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Systemic): May decrease the serum concentration of Levodopa-Foslevodopa.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iron Preparations: May decrease the serum concentration of Levodopa. Only applies to oral iron preparations. Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: May diminish the therapeutic effect of Levodopa-Foslevodopa.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist). Kava Kava may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Levodopa-Foslevodopa may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methionine: May diminish the therapeutic effect of Levodopa-Foslevodopa. Management: Avoid large daily doses of methionine in patients receiving levodopa (clinical studies showing interaction used 4.5 g methionine daily). More typical doses of methionine (eg, 500 mg) may not cause a problem.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Methotrimeprazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: Levodopa-Foslevodopa may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Of particular concern is the development of hypertensive reactions when levodopa is used with nonselective MAOI. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Type B): Levodopa-Foslevodopa may enhance the orthostatic hypotensive effect of Monoamine Oxidase Inhibitors (Type B). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May diminish the therapeutic effect of Levodopa-Foslevodopa. Management: Concurrent use of a multivitamin and levodopa (without carbidopa) should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May diminish the therapeutic effect of Levodopa. Multivitamins/Minerals (with ADEK, Folate, Iron) may decrease the serum concentration of Levodopa. Only applies to oral iron-containing preparations. Management: Separate doses of these agents by 2 or more hours.  Monitor for decreased levodopa effects, particularly if doses cannot be separated.  Concurrent use of a multivitamin and levodopa (without carbidopa) should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May diminish the therapeutic effect of Levodopa-Foslevodopa. Management: Concurrent use of a multivitamin and levodopa (without carbidopa) should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Papaverine: May enhance the hypotensive effect of Levodopa-Foslevodopa. Papaverine may diminish the therapeutic effect of Levodopa-Foslevodopa.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pyridoxine: May diminish the therapeutic effect of Levodopa-Foslevodopa. Management: The concomitant use of pyridoxine and levodopa (in the absence of a dopa decarboxylase inhibitor (DDI)) should be avoided. Use of a DDI (eg, carbidopa) with levodopa will essentially eliminate the risk of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reserpine: Levodopa-Foslevodopa may enhance the hypotensive effect of Reserpine. Reserpine may diminish the therapeutic effect of Levodopa-Foslevodopa.  Management: Consider alternatives to the coadministration of levodopa and reserpine. If combined, monitor for reduced levodopa efficacy and hypotension.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sapropterin: May enhance the adverse/toxic effect of Levodopa-Foslevodopa.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spiramycin: May decrease the serum concentration of Carbidopa. And thus may decrease the effectiveness of levodopa.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors: May diminish the therapeutic effect of Levodopa-Foslevodopa. Management: Consider alternatives to the coadministration of levodopa and vesicular monoamine transporter 2 (VMAT2) inhibitors. If combined, monitor for reduced levodopa efficacy.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F187990"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">High protein diets have the potential to impair levodopa absorption; levodopa competes with certain amino acids for transport across the gut wall or across the blood-brain barrier. Management: Avoid high protein diets. </p></div>
<div class="block pri drugH1Div" id="F187985"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Carbidopa can be detected in the umbilical cord, but absorption in fetal tissue is minimal. Levodopa crosses the placenta and can be metabolized by the fetus and detected in fetal tissue (Merchant 1995).</p>
<p style="text-indent:0em;margin-top:2em;">The incidence of Parkinson disease in pregnancy is relatively rare, and although information related to the use of carbidopa/levodopa in pregnant women is limited (Ball 1995; Cook 1985; Golbe 1987; Serikawa 2011; Shulman 2000; Tüfekçioğlu 2018; Zlotnik 2014), this combination has the most outcome information available for the treatment of pregnant women (Seier 2017). Current guidelines note that the available information is insufficient to make a recommendation for the treatment of restless legs syndrome in pregnant women (Aurora 2012).</p></div>
<div class="block brc drugH1Div" id="F21737065"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Levodopa is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">A study was done in one breastfeeding woman at 4.5 months postpartum who had been taking carbidopa/levodopa for several years. Regardless of the formulation (sustained release or immediate release), peak levodopa concentrations in the breast milk were found ~3 hours after the maternal dose and returned to baseline ~6 hours after the dose. The highest milk concentration (3.47 nmol/L) was found following the immediate release tablet, and this was 27% of the peak maternal plasma concentration (occurring 30 minutes after the dose) and ~40% of the simultaneous plasma concentration. Carbidopa was not evaluated (Thulin 1998).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Lactation may be inhibited by levodopa.</p></div>
<div class="block dic drugH1Div" id="F187986"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Avoid high protein diets (&gt;2 g/kg) which may decrease the efficacy of levodopa via competition with amino acids in crossing the blood-brain barrier. Some products may contain phenylalanine.</p></div>
<div class="block mop drugH1Div" id="F187972"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs and symptoms of Parkinson disease; periodic hepatic function tests, BUN, creatinine, and CBC; periodic skin examinations; signs and symptoms of postural hypotension (eg, BP, standing and sitting/supine; especially during dose escalation); symptoms of dyskinesias, mental status changes; cardiac function (particularly during initial dosage adjustment), IOP (in patients with glaucoma); signs and symptoms of Parkinsonism-hyperpyrexia syndrome, especially if abrupt dose reduction or discontinuation required (as with surgery); drowsiness or sleepiness; signs of depression (including suicidal thoughts); signs and symptoms of peripheral neuropathy prior to therapy and periodically during therapy; risk factors for neuropathy prior to initiation (eg, deficiency of vitamin B<sub>6</sub> and/or B<sub>12</sub>, diabetes mellitus, hypothyroidism). Monitor closely for melanoma.</p>
<p style="text-indent:0em;margin-top:2em;">Additional Canadian labeling recommendations include vitamin B<sub>12</sub>, vitamin B<sub>6</sub>, folic acid, homocysteine, and methylmalonic acid levels prior to initiation and regularly thereafter (Duodopa Canadian product monograph).</p></div>
<div class="block pha drugH1Div" id="F187961"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Parkinson disease symptoms are due to a lack of striatal dopamine; levodopa circulates in the plasma to the blood-brain-barrier (BBB), where it crosses, to be converted by striatal enzymes to dopamine; carbidopa inhibits the peripheral plasma breakdown of levodopa by inhibiting its decarboxylation, and thereby increases available levodopa at the BBB</p></div>
<div class="block phk drugH1Div" id="F187980"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Absorption of levodopa may be decreased with high-fat, high-calorie, or high-protein meal.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Levodopa: 0.9 to 1.6 L/kg (in presence of carbidopa), crosses the blood-brain barrier; Carbidopa: Does not cross the blood-brain barrier.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Levodopa: 10% to 30%; Carbidopa: ~36%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Levodopa has two major pathways (decarboxylation and O-methylation) and two minor pathways (transamination and oxidation) of metabolism; Carbidopa inhibits the decarboxylation of levodopa to dopamine in the peripheral tissue to allow greater levodopa distribution into the CNS.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability:</p>
<p style="text-indent:-2em;margin-left:4em;">Controlled and extended release: Levodopa: Bioavailability is ~70% to 75% relative to availability from IR formulation; Carbidopa: Bioavailability is ~50% to 58% relative to availability from IR formulation.</p>
<p style="text-indent:-2em;margin-left:4em;">Intestinal gel [Canadian product]: Levodopa: Similar bioavailability relative to oral administration of tablet formulations (81% to 98%).</p>
<p style="text-indent:-2em;margin-left:4em;">Intestinal suspension: Levodopa: 97% relative to oral IR tablets.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Levodopa (in presence of carbidopa): Immediate release: 1.5 to 2 hours; controlled release: 1.6 hours; extended release: 1.9 hours (Hsu 2015; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak (levodopa component): Immediate release: 0.5 to 1 hour; controlled release: 1.5 to 2 hours; extended release: 1 to 4.5 hours (Hsu 2015; manufacturer's labeling). Intestinal gel [Canadian product]: 2.9 hours with therapeutic plasma levels reached 10 to 30 minutes following morning bolus dose; intestinal suspension: 2.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine.</p></div>
<div class="block phksp drugH1Div" id="F51154237"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Older adult: The AUC and C<sub>max</sub> of levodopa may be increased in elderly patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Increased carbidopa and levodopa peak concentrations and systemic exposure in females compared with males.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F187987"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo levocarb | Duodopa | Levomed | Sinemet</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Lebocar | Lebocar ap | Lecarge | Sinemet cr | Zomer</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Levocar | Sinemet</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo levocarb | Apo levodopa/carbidopa | Duodopa | Kinson | Levo/Carbidopa sandoz | Levohexal | Sinacarb | Sinadopa | Sinemet</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Carlev | Co dopa | D Dopa Plus | Levopa | Perkidopa | Syndopa | Twindopa | Zimox</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Sinemet</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Duodopa | Sinemet | Sinemet cr | Sinepar</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Carbidol | Carbidopa/levodopa | Cronomet | Duodopa | Levocarb | Parkidopa | Parklen | Sinemet</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Carbidopa levodopa | Duodopa | Sinemet | Sinemet cr | Zamdopa</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Grifoparkin | Levofamil | Protonis | Saniter Compuesto | Sinemet cr</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Carbidopa + l-dopa | Carbidopa and levodopa | Sinemet</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cinetol | Levodopa carbidopa | Levodopa/carbidopa sandoz | Parken | Sinemet</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Duodopa | Isicom | Lecardop | Levodopa/Carbidopa mylan | Nakom | Nakom mite | Sinemet cr</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Dopadura c | Duodopa | Isicom | Levo c al | Levobeta c | Levocarb | Levocarb 1 A Pharma | LevoCarb 1A Pharma | Levocomp | Levodop | Levodopa c comp | Levodopa carbid | Levodopa Comp | Levodopa comp c | Levodopa ratio comp | Levodopa RPH | Levodopa/carbidopa | Levodopa/Carbidopa AbZ | Levodopa/Carbidopa CT | Levodopa/Carbidopa Fair Med | Levodopa/carbidopa neuraxpharm | Levodopa/carbidopa ratiopharm | Nacom | Sinemet | Striaton | Toniform | Tremopar</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Cloisone | Dolxen | Eurodopa | Levodopa/carbidopa sandoz | Parkil | Sinemet | Sorkinox</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Aldana xr | Carbidopa levodopa | Carbidopa y levodopa | Carbidopa/levodopa | Cloisone | Grifoparkin | Levocarchem | Parken | Sinemet cr | Syndopa</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Duodopa | Isicom | Nakom | Sinemet cr</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Carbolev | Lecardopa | Levocar | Parkidopa | Shatoo | Sinemet</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Carbidopa/levodopa davur | Levodopa/carbidopa ratiopharm | Levodopa/carbidopa teva | Sinemet</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Carbidopa and levodopa | Credanil</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Carbidopa/Levodopa Orion | Duodopa | Kardopal | Levocar | Levodopa/carbidopa accord | Sinemet | Sinemet depot</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Carbidopa Levodopa Teva | Levodopa/carbidopa accord lp | Sinemet</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Apodespan | Caramet | Co careldopa | Co careldopa kent | Numient | Sinemet | Tilolec</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Credanil | Duodopa | Sinemet | Sinemet cr | Sinemet lp | Sinemet Plus | Zimox</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo levocarb | Levomed | Levomet | Sinemet</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Nakom | Sinemet</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Carbidopa-levodopa-b | Duellin | Duodopa | Levodopa/carbidopa teva | Sinemet</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Anti-parkinson</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Caramet | Carbidopa/levodopa fairmed | Duodopa | Sinemet</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Dopicar | Sinemet cr</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Duodopa | Duodopa plus | Lcd | Levopa-c | Neocare | Paradopa | Parkimet plus | Sinemet | Syndopa | Syndopa plus | Tidomet</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Bidopa</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Carbidopa e levodopa accord | Carbidopa/levodopa | Duodopa | Sinemet</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Credanil | Sinemet</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Carcopa | Dopacol | Duodopa | Leprinton | Menesit | Neodopaston | Parkiston</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Sinemet</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Duodopa intestinal gel | Isicom | Levoda | Perkin 25-100 | Perkin 25-250 | Perkin cr | Promet | Sinemet | Sinemet cr</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Duodopa | Levacin | Sinemet</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Carlevo | Sinemet</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Isicom | Levodopa/carbidopa fair med healthcare | Levomed | Nakom | Sinemet | Sinepar | Syndopa | Tidomet plus | Zimox</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Sinemet</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Duodopa | Nakom | Sinemet | Zimox</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Cloisone | Lemdopa | Racovel | Rinzovar | Sinemet | Sinemet cr | Ternovag</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo levocarb | Credanil | Levomed | Sinemet</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Pardopa | Sinamet</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Duodopa | Levodopa/carbidopa | Levodopa/carbidopa accord | Levodopa/Carbidopa mylan | Levodopa/carbidopa neuraxph | Levodopa/carbidopa pch | Levodopa/carbidopa pch retard | Numient | Sinemet | Sinemet lp | Sinemet Plus</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Carbidopa/levodopa fairmed | Duodopa | Levocomp | Levodop neuraxpharm | Sinemet | Sinemet Depot mite</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Kinson | Sindopa | Sinemet</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Carbidopa + levodopa | Carbidopa/levodopa | Carbipharm | Cinetol | Cloisone | Darpott | Grifoparkin | Lecarge | Licebral amex | Mebexit | Sindrob | Sinemet cr | Sulconar</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Carbidel | Lavida | Ledocar | Medolev | Pardopa | Parkimet | Parkimet CR | Sinedin | Sinemet | Sinemet cr | Tidomet</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cardop | Dopasel | Neudopa | Sinedopa | Sinemet</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Duodopa | Nakom | Pardopa | Poldomet | Sinemet cr</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Carbidopa and levodopa | Carbidopa/levodopa | Dhivy | Duopa | Sinemet cr</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Dopadura c | Duodopa | Ledopsan | Levodopa + Carbidopa fairmed | Sinemet cr</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Carbidopa + levodopa prosalud | Grifoparkin | Istonil | Levodopa carbidopa cellofarm | Levodopa carbidopa dasanti | Levodopa carbidopa heisecke | Licebral | Nestplena | Sinemet | Sionus</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Duodopa | Sinemet</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Credanil | Duodopa | Isicom | Zimox</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Carbidopa levodopa | Carbidopa/levodopa | Duellin | Duodopa | Nakom | Sinemet | Sinemet cr | Syndopa | Tidomet | Tidomet forte | Tidomet ls | Tidomet plus | Tremonorm | Vero levocarbidopa</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo levocarb | Duodopa | Levomed | Sinemet | Sinemet Plus | Syndopa</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Carbidopa/levodopa fairmed | Duodopa | Karbidopa/levodopa ebb | Levocar | Levodopa/carbidopa accord | Levodopa/carbidopa ratiopharm | Sinemet | Sinemet Depot mite</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Cardopar | Sinemet | Tidomet</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Nakom</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Duodopa | Isicom | Nakom | Sinemet | Sinemet cr</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Duodopa | Levomed | Levomed 25/250 | Levomet | Levomet 25/250 | Sinemet | Syndopa | Tidomet</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Dopadex sr | Sinemet</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bidopar | Duodopa | Lecadopa | Majormet | Sinemet | Sinemet cr</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Carbidopa/levodopa | Carbilevodop | Confundus | Levocom | Levocom retard acino | Nakom | Sindopa | Sinemet</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Tidomet</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Lebocar | Levomet | Licebral | Sinemet cr</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Levodopa carbidopa | Levodopa, carbidopa | Parken | Rotidin | Sinemet | Sinemet cr | Sorkinox | Welldopa</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Creamec | Masopen | Vedilma</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Carbilev | Lecardop | Sinemet | Teva carbi levo</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AA-Levocarb.2020.03">
<a name="AA-Levocarb.2020.03"></a>AA-Levocarb CR (carbidopa/levodopa) extended-release tablets [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30033887">
<a name="30033887"></a>Anang JBM. Levodopa-carbidopa-related rash in Parkinson's disease: a case series. <i>Can J Neurol Sci</i>. 2018;45(5):588-589. doi:10.1017/cjn.2018.58<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/30033887/pubmed" id="30033887" target="_blank">30033887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851801">
<a name="22851801"></a>Aurora RN, Kristo DA, Bista SR, et al; American Academy of Sleep Medicine. The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine clinical practice guideline. <i>Sleep</i>. 2012;35(8):1039-1062.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/22851801/pubmed" id="22851801" target="_blank">22851801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31032135">
<a name="31032135"></a>Ayobello A, Saway B, Greenage M. Attempted suicide in a Parkinsonian patient treated with DBS of the VIM and high dose carbidopa-levodopa. <i>Case Rep Psychiatry</i>. 2019;2019:2903762. doi:10.1155/2019/2903762<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/31032135/pubmed" id="31032135" target="_blank">31032135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7885346">
<a name="7885346"></a>Ball MC, Sagar HJ. Levodopa in pregnancy. <i>Mov Disord</i>. 1995;10(1):115.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/7885346/pubmed" id="7885346" target="_blank">7885346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20212233">
<a name="20212233"></a>Bertoni JM, Arlette JP, Fernandez HH, et al. Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. <i>Arch Neurol</i>. 2010;67(3):347-352. doi:10.1001/archneurol.2010.1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/20212233/pubmed" id="20212233" target="_blank">20212233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25491470">
<a name="25491470"></a>Beaulieu-Boire I, Lang AE. Behavioral effects of levodopa. <i>Mov Disord</i>. 2015;30(1):90-102. doi:10.1002/mds.26121<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/25491470/pubmed" id="25491470" target="_blank">25491470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9018028">
<a name="9018028"></a>Block G, Liss C, Reines S, Irr J, Nibbelink D; The CR First Study Group. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. <i>Eur Neurol</i>. 1997;37(1):23-27. doi:10.1159/000117399<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/9018028/pubmed" id="9018028" target="_blank">9018028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19339647">
<a name="19339647"></a>Bostwick JM, Hecksel KA, Stevens SR, Bower JH, Ahlskog JE. Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. <i>Mayo Clin Proc</i>. 2009;84(4):310-316. doi:10.1016/S0025-6196(11)60538-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/19339647/pubmed" id="19339647" target="_blank">19339647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15556835">
<a name="15556835"></a>Bouhaddi M, Vuillier F, Fortrat JO, et al. Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson's disease: involvement of L-dopa therapy. <i>Auton Neurosci</i>. 2004;116(1-2):30-38. doi:10.1016/j.autneu.2004.06.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/15556835/pubmed" id="15556835" target="_blank">15556835</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30363427">
<a name="30363427"></a>Burack M, Aldred J, Zadikoff C, et al. Implementing levodopa-carbidopa intestinal gel for Parkinson disease: insights from US practitioners. <i>Mov Disord Clin Pract</i>. 2018;5(4):383-393. doi:10.1002/mdc3.12630<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/30363427/pubmed" id="30363427" target="_blank">30363427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30755870">
<a name="30755870"></a>Campa D, Ariello M, Castaldo R, Zibella F, Ferrazza P, Del Gaudio S. A fatal case of neuroleptic malignant syndrome after paralytic bowel in a patient taking antiparkinson medication. <i>Eur J Case Rep Intern Med</i>. 2016;3(4):000368. doi:10.12890/2016_000368<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/30755870/pubmed" id="30755870" target="_blank">30755870</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Carbidopa/levodopa extended-release tablets [prescribing information]. BluePoint Laboratories; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7876846">
<a name="7876846"></a>Collins SJ, Ahlskog JE, Parisi JE, Maraganore DM. Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. <i>J Neurol Neurosurg Psychiatry</i>. 1995;58(2):167-173. doi:10.1136/jnnp.58.2.167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/7876846/pubmed" id="7876846" target="_blank">7876846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3978654">
<a name="3978654"></a>Cook DG, Klawans HL. Levodopa During Pregnancy. <i>Clin Neuropharmacol</i>. 1985;8(1):93-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/3978654/pubmed" id="3978654" target="_blank">3978654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25707301">
<a name="25707301"></a>Cordano C, Pardini M, Cellerino M, Schenone A, Marino F, Cosentino M. Levodopa-induced neutropenia. <i>Parkinsonism Relat Disord</i>. 2015;21(4):423-425. doi:10.1016/j.parkreldis.2015.02.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/25707301/pubmed" id="25707301" target="_blank">25707301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dhivy.1">
<a name="Dhivy.1"></a>Dhivy (carbidopa/levodopa) tablet [prescribing information]. Alpharetta, GA: Avion Pharmaceuticals LLC; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32761061">
<a name="32761061"></a>Drew DS, Muhammed K, Baig F, et al. Dopamine and reward hypersensitivity in Parkinson's disease with impulse control disorder. <i>Brain</i>. 2020;143(8):2502-2518. doi:10.1093/brain/awaa198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/32761061/pubmed" id="32761061" target="_blank">32761061</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Duodopa (carbidopa/levodopa) intestinal gel [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; April 2022.</div>
</li>
<li>
<div class="reference">
                  Duopa (carbidopa/levodopa) [prescribing information]. North Chicago, IL: AbbVie Inc; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9085489">
<a name="9085489"></a>Earley CJ, Allen RP. Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. <i>Sleep</i>. 1996;19(10):801-810. doi:10.1093/sleep/19.10.801<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/9085489/pubmed" id="9085489" target="_blank">9085489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28243505">
<a name="28243505"></a>Espay AJ, Pagan FL, Walter BL, et al. Optimizing extended-release carbidopa/levodopa in Parkinson disease: consensus on conversion from standard therapy. <i>Neurol Clin Pract</i>. 2017;7(1):86-93. doi:10.1212/CPJ.0000000000000316<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/28243505/pubmed" id="28243505" target="_blank">28243505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15590952">
<a name="15590952"></a>Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. <i>N Engl J Med</i>. 2004;351(24):2498-2508. doi:10.1056/NEJMoa033447<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/15590952/pubmed" id="15590952" target="_blank">15590952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23287001">
<a name="23287001"></a>Fernandez HH, Vanagunas A, Odin P, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. <i>Parkinsonism Relat Disord</i>. 2013;19(3):339-345. doi:10.1016/j.parkreldis.2012.11.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/23287001/pubmed" id="23287001" target="_blank">23287001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15811084">
<a name="15811084"></a>Forschner A, Fierlbeck G. Localized pemphigoid on the soles of both feet. <i>Int J Dermatol</i>. 2005;44(4):312-314. doi:10.1111/j.1365-4632.2004.01932.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/15811084/pubmed" id="15811084" target="_blank">15811084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22937989">
<a name="22937989"></a>Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al; European Federation of Neurological Societies; European Neurological Society; European Sleep Research Society. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. <i>Eur J Neurol</i>. 2012;19(11):1385-1396. doi:10.1111/j.1468-1331.2012.03853.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/22937989/pubmed" id="22937989" target="_blank">22937989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27448465">
<a name="27448465"></a>Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. <i>Sleep Med</i>. 2016;21:1-11. doi:10.1016/j.sleep.2016.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/27448465/pubmed" id="27448465" target="_blank">27448465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18725592">
<a name="18725592"></a>Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. <i>Neurology</i>. 2008;71(9):670-676. doi:10.1212/01.wnl.0000324625.00404.15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/18725592/pubmed" id="18725592" target="_blank">18725592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3601093">
<a name="3601093"></a>Golbe LI. Parkinson's Disease and Pregnancy. <i>Neurology</i>. 1987;37(7):1245-1249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/3601093/pubmed" id="3601093" target="_blank">3601093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18823039">
<a name="18823039"></a>Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. <i>Mov Disord</i>. 2008;23(15):2248-2250. doi:10.1002/mds.22322<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/18823039/pubmed" id="18823039" target="_blank">18823039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5000569">
<a name="5000569"></a>Goodwin FK. Psychiatric side effects of levodopa in man. <i>JAMA</i>. 1971;218(13):1915-1920.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/5000569/pubmed" id="5000569" target="_blank">5000569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31501181">
<a name="31501181"></a>Grimes D, Fitzpatrick M, Gordon J, et al. Canadian guideline for Parkinson disease. <i>CMAJ</i>. 2019;191(36):E989-E1004. doi:10.1503/cmaj.181504<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/31501181/pubmed" id="31501181" target="_blank">31501181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2900293">
<a name="2900293"></a>Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. <i>J Neurol Neurosurg Psychiatry</i>. 1988;51(6):850-854. doi:10.1136/jnnp.51.6.850<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/2900293/pubmed" id="2900293" target="_blank">2900293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7356419">
<a name="7356419"></a>Hoehn MM. Increased dosage of carbidopa in patients with Parkinson's disease receiving low doses of levodopa. A pilot study. <i>Arch Neurol</i>. 1980;37(3):146-149. doi:10.1001/archneur.1980.00500520044006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/7356419/pubmed" id="7356419" target="_blank">7356419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28467028">
<a name="28467028"></a>Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. <i>Mov Disord</i>. 2017;32(6):853-864. doi:10.1002/mds.26987<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/28467028/pubmed" id="28467028" target="_blank">28467028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25855267">
<a name="25855267"></a>Hsu A, Yao HM, Gupta S, Modi NB. Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet), sustained-release carbidopa-levodopa (Sinemet CR), and carbidopa-levodopa-entacapone (Stalevo). <i>J Clin Pharmacol</i>. 2015;55(9):995-1003. doi:10.1002/jcph.514<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/25855267/pubmed" id="25855267" target="_blank">25855267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5030025">
<a name="5030025"></a>Joseph C. Occurrence of positive Coombs test in patients treated with levodopa. <i>N Engl J Med</i>. 1972;286(26):1401-1402. doi:10.1056/NEJM197206292862609<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/5030025/pubmed" id="5030025" target="_blank">5030025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4082903">
<a name="4082903"></a>Kaakkola S, Männistö PT, Nissinen E, Vuorela A, Mäntylä R. The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa. <i>Acta Neurol Scand</i>. 1985;72(4):385-391. doi:10.1111/j.1600-0404.1985.tb00888.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/4082903/pubmed" id="4082903" target="_blank">4082903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20404676">
<a name="20404676"></a>Kim JH, Kwon TH, Koh SB, Park JY. Parkinsonism-hyperpyrexia syndrome after deep brain stimulation surgery: case report. <i>Neurosurgery</i>. 2010;66(5):E1029. doi:10.1227/01.NEU.0000367799.38332.43<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/20404676/pubmed" id="20404676" target="_blank">20404676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9678313">
<a name="9678313"></a>Kompoliti K, Goetz CG, Boeve BF, et al. Clinical presentation and pharmacological therapy in corticobasal degeneration. <i>Arch Neurol</i>. 1998;55(7):957-961. doi:10.1001/archneur.55.7.957<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/9678313/pubmed" id="9678313" target="_blank">9678313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7605692">
<a name="7605692"></a>Kondo T, Mochizuki H, Ueda G, et al. A 51-year-old man with early onset parkinsonism. Article in Japanese. <i>No To Shinkei</i>. 1995;47(6):603-612.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/7605692/pubmed" id="7605692" target="_blank">7605692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11030798">
<a name="11030798"></a>Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. <i>Arch Neurol</i>. 2000;57(10):1461-1463. doi:10.1001/archneur.57.10.1461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/11030798/pubmed" id="11030798" target="_blank">11030798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24868421">
<a name="24868421"></a>Lee KE, Kang HS, Yu HJ, Roh SY. Thrombocytopenia associated with levodopa treatment. <i>J Mov Disord</i>. 2013;6(1):21-22. doi:10.14802/jmd.13005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/24868421/pubmed" id="24868421" target="_blank">24868421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31619083">
<a name="31619083"></a>Leta V, Jenner P, Chaudhuri KR, Antonini A. Can therapeutic strategies prevent and manage dyskinesia in Parkinson's disease? An update. <i>Expert Opin Drug Saf</i>. 2019;18(12):1203-1218. doi:10.1080/14740338.2019.1681966<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/31619083/pubmed" id="31619083" target="_blank">31619083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25962554">
<a name="25962554"></a>Lew MF, Slevin JT, Krüger R, et al. Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials. <i>Parkinsonism Relat Disord</i>. 2015;21(7):742-748. doi:10.1016/j.parkreldis.2015.04.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/25962554/pubmed" id="25962554" target="_blank">25962554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-402877">
<a name="402877"></a>Linström FD, Liedén G, Enström MS. Dose-related levodopa-induced haemolytic anaemia. <i>Ann Intern Med</i>. 1977;86(3):298-300. doi:10.7326/0003-4819-86-3-298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/402877/pubmed" id="402877" target="_blank">402877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20584946">
<a name="20584946"></a>Ling H, O'Sullivan SS, Holton JL, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. <i>Brain</i>. 2010;133(pt 7):2045-2057. doi:10.1093/brain/awq123<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/20584946/pubmed" id="20584946" target="_blank">20584946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-lodosyn.2020">
<a name="lodosyn.2020"></a>Lodosyn (carbidopa) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26025783">
<a name="26025783"></a>Low PA, Reich SG, Jankovic J, et al. Natural history of multiple system atrophy in the USA: a prospective cohort study. <i>Lancet Neurol</i>. 2015;14(7):710-719. doi:10.1016/S1474-4422(15)00058-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/26025783/pubmed" id="26025783" target="_blank">26025783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4834974">
<a name="4834974"></a>Markham C, Diamond SG, Treciokas LJ. Carbidopa in Parkinson disease and in nausea and vomiting of levodopa. <i>Arch Neurol</i>. 1974;31(2):128-133. doi:10.1001/archneur.1974.00490380076010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/4834974/pubmed" id="4834974" target="_blank">4834974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5550880">
<a name="5550880"></a>Marshall A, Williams MJ. Alopecia and levodopa. <i>Br Med J</i>. 1971;2(5752):47. doi:10.1136/bmj.2.5752.47<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/5550880/pubmed" id="5550880" target="_blank">5550880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8527007">
<a name="8527007"></a>Merchant CA, Cohen G, Mytilineou C, et al. Human transplacental transfer of carbidopa/levodopa. <i>J Neural Transm Park Dis Dement Sect</i>. 1995;9(2-3):239-242.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/8527007/pubmed" id="8527007" target="_blank">8527007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16107351">
<a name="16107351"></a>Molloy S, McKeith IG, O'Brien JT, Burn DJ. The role of levodopa in the management of dementia with Lewy bodies. <i>J Neurol Neurosurg Psychiatry</i>. 2005;76(9):1200-1203. doi:10.1136/jnnp.2004.052332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/16107351/pubmed" id="16107351" target="_blank">16107351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18712508">
<a name="18712508"></a>Newman EJ, Grosset DG, Kennedy PG. The parkinsonism-hyperpyrexia syndrome. <i>Neurocrit Care</i>. 2009;10(1):136-140. doi:10.1007/s12028-008-9125-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/18712508/pubmed" id="18712508" target="_blank">18712508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30838990">
<a name="30838990"></a>Ng CF, Tiau PW, Tan HJ, Norlinah MI. Levodopa-induced myocardial infarction in a patient with Parkinson's disease and severe coronary artery disease. <i>J R Coll Physicians Edinb</i>. 2019;49(1):37-39. doi:10.4997/JRCPE.2019.108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/30838990/pubmed" id="30838990" target="_blank">30838990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9107252">
<a name="9107252"></a>Niedermaier G, Briner V. Henoch-Schönlein syndrome induced by carbidopa/levodopa. <i>Lancet</i>. 1997;349(9058):1071-1072. doi:10.1016/S0140-6736(05)62294-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/9107252/pubmed" id="9107252" target="_blank">9107252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12782919">
<a name="12782919"></a>Nyholm D, Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. <i>Clin Neuropharmacol</i>. 2003;26(3):156-163. doi:10.1097/00002826-200305000-00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/12782919/pubmed" id="12782919" target="_blank">12782919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24361112">
<a name="24361112"></a>Olanow CW, Kieburtz K, Odin P, et al; LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. <i>Lancet Neurol</i>. 2014;13(2):141-149. doi:10.1016/S1474-4422(13)70293-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/24361112/pubmed" id="24361112" target="_blank">24361112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oliver.1">
<a name="Oliver.1"></a>Oliver D, Veronese S. Palliative approach to Parkinson disease and parkinsonian disorders. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24055014">
<a name="24055014"></a>Pahwa R, Lyons KE, Hauser RA, et al; APEX-PD Investigators. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. <i>Parkinsonism Relat Disord</i>. 2014;20(2):142-148. doi:10.1016/j.parkreldis.2013.08.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/24055014/pubmed" id="24055014" target="_blank">24055014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22613365">
<a name="22613365"></a>Perry D, Birthi P, Salles S, McDowell S. Neuroleptic malignant syndrome associated with the use of carbidopa/levodopa for dystonia in persons with cerebral palsy. <i>PM R</i>. 2012;4(5):383-384. doi:10.1016/j.pmrj.2011.11.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/22613365/pubmed" id="22613365" target="_blank">22613365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30649026">
<a name="30649026"></a>Ramírez-Gómez CC, Zúñiga-Ramírez C, Contartese ML, Montilla V, Gramajo J, Micheli F. Blepharospasm as a manifestation of peak of dose dyskinesia in Parkinson disease. <i>Clin Neuropharmacol</i>. 2019;42(1):14-16. doi:10.1097/WNF.0000000000000316<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/30649026/pubmed" id="30649026" target="_blank">30649026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26946221">
<a name="26946221"></a>Ricciardi L, Bove F, Espay KJ, et al. 24-hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease. <i>Mov Disord</i>. 2016;31(4):597-598. doi:10.1002/mds.26564<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/26946221/pubmed" id="26946221" target="_blank">26946221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30838307">
<a name="30838307"></a>Romagnolo A, Merola A, Artusi CA, Rizzone MG, Zibetti M, Lopiano L. Levodopa-induced neuropathy: a systematic review. <i>Mov Disord Clin Pract</i>. 2018;6(2):96-103. doi:10.1002/mdc3.12688<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/30838307/pubmed" id="30838307" target="_blank">30838307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rytary.1">
<a name="Rytary.1"></a>Rytary (carbidopa/levodopa) [prescribing information]. Bridgewater, NJ: Amneal Specialty; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23948989">
<a name="23948989"></a>Salat D, Tolosa E. Levodopa in the treatment of Parkinson's disease: current status and new developments. <i>J Parkinsons Dis</i>. 2013;3(3):255-269. doi:10.3233/JPD-130186<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/23948989/pubmed" id="23948989" target="_blank">23948989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28506531">
<a name="28506531"></a>Seier M, Hiller A. Parkinson's disease and pregnancy: an updated review. <i>Parkinsonism Relat Disord</i>. 2017;40:11-17. doi:10.1016/j.parkreldis.2017.05.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/28506531/pubmed" id="28506531" target="_blank">28506531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21682904">
<a name="21682904"></a>Serikawa T, Shimohata T, Akashi M, et al. Successful twin pregnancy in a patient with parkin-associated autosomal recessive juvenile parkinsonism. <i>BMC Neurol</i>. 2011;11:72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/21682904/pubmed" id="21682904" target="_blank">21682904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12573874">
<a name="12573874"></a>Serrano-Dueñas M. Neuroleptic malignant syndrome-like, or--dopaminergic malignant syndrome--due to levodopa therapy withdrawal. Clinical features in 11 patients. <i>Parkinsonism Relat Disord</i>. 2003;9(3):175-178. doi:10.1016/s1353-8020(02)00035-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/12573874/pubmed" id="12573874" target="_blank">12573874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32509684">
<a name="32509684"></a>Shihabudheen P, Anver PC, Uvais NA, Mohammed TP. Dose-dependent L-dopa/carbidopa-induced hyponatremia presenting with hiccups. <i>J Family Med Prim Care</i>. 2020;9(3):1749-1751. doi:10.4103/jfmpc.jfmpc_1044_19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/32509684/pubmed" id="32509684" target="_blank">32509684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10634252">
<a name="10634252"></a>Shulman LM, Minagar A, Weiner WJ. The effect of pregnancy in Parkinson's disease. <i>Mov Disord</i>. 2000;15(1):132-135.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/10634252/pubmed" id="10634252" target="_blank">10634252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15244390">
<a name="15244390"></a>Silber MH, Ehrenberg BL, Allen RP, et al; Medical Advisory Board of the Restless Legs Syndrome Foundation. An algorithm for the management of restless legs syndrome. <i>Mayo Clin Proc</i>. 2004;79(7):916-922.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/15244390/pubmed" id="15244390" target="_blank">15244390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31427383">
<a name="31427383"></a>Simonet C, Tolosa E, Camara A, Valldeoriola F. Emergencies and critical issues in Parkinson's disease. <i>Pract Neurol</i>. 2020;20(1):15-25. doi:10.1136/practneurol-2018-002075<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/31427383/pubmed" id="31427383" target="_blank">31427383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15857324">
<a name="15857324"></a>Simsek T, Eryilmaz T, Acaroglu G. Efficacy of levodopa and carbidopa on visual function in patients with non-arteritic anterior ischaemic optic neuropathy. <i>Int J Clin Pract</i>. 2005;59(3):287-290. doi:10.1111/j.1742-1241.2005.00462.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/15857324/pubmed" id="15857324" target="_blank">15857324</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sinemet (carbidopa/levodopa) [prescribing information]. Jersey City, NJ: Organon LLC; June 2021.</div>
</li>
<li>
<div class="reference">
                  Sinemet (carbidopa/levodopa) [product monograph]. Kirkland, Quebec, Canada: Organon Canada Inc; April 2021.</div>
</li>
<li>
<div class="reference">
                  Sinemet CR (carbidopa/levodopa) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; April 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8750001">
<a name="8750001"></a>Spieker S, Stetter F, Klockgether T. Zotepine in levodopa-induced Psychosis. <i>Mov Disord</i>. 1995;10(6):795-797. doi:10.1002/mds.870100615<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/8750001/pubmed" id="8750001" target="_blank">8750001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spindler.1">
<a name="Spindler.1"></a>Spindler MA. Initial pharmacologic treatment of Parkinson disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9633767">
<a name="9633767"></a>Thulin PC, Woodward WR, Carter JH, et al. Levodopa in human breast milk: clinical implications. <i>Neurology</i>. 1998;50(6):1920-1921.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/9633767/pubmed" id="9633767" target="_blank">9633767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19252795">
<a name="19252795"></a>Tinazzi M, Antonini A, Bovi T, et al. Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. <i>J Neurol</i>. 2009;256(6):910-915. doi:10.1007/s00415-009-5039-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/19252795/pubmed" id="19252795" target="_blank">19252795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29926223">
<a name="29926223"></a>Tüfekçioğlu Z, Hanağası H, Yalçın Çakmaklı G, et al. Use of anti-Parkinson medication during pregnancy: a case series. <i>J Neurol</i>. 2018;265(8):1922-1929. doi:10.1007/s00415-018-8937-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/29926223/pubmed" id="29926223" target="_blank">29926223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28229895">
<a name="28229895"></a>Voon V, Napier TC, Frank MJ, et al. Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update. <i>Lancet Neurol</i>. 2017;16(3):238-250. doi:10.1016/S1474-4422(17)30004-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/28229895/pubmed" id="28229895" target="_blank">28229895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25370355">
<a name="25370355"></a>Weintraub D, David AS, Evans AH, Grant JE, Stacy M. Clinical spectrum of impulse control disorders in Parkinson's disease [published correction appears in <i>Mov Disord</i>. 2015;30(7):1010]. <i>Mov Disord</i>. 2015;30(2):121-127. doi:10.1002/mds.26016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/25370355/pubmed" id="25370355" target="_blank">25370355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27856776">
<a name="27856776"></a>Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: treatment of restless legs syndrome in adults: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2016;87(24):2585-2593.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/27856776/pubmed" id="27856776" target="_blank">27856776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35949204">
<a name="35949204"></a>Wise A, Lemus HN, Fields M, Swan M, Bressman S. Refractory seizures secondary to vitamin B6 deficiency in Parkinson disease: the role of carbidopa-levodopa. <i>Case Rep Neurol</i>. 2022;14(2):291-295. doi:10.1159/000525234<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/35949204/pubmed" id="35949204" target="_blank">35949204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2685649">
<a name="2685649"></a>Yeh KC, August TF, Bush DF, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. <i>Neurology.</i> 1989;39(11 Suppl 2):25-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/2685649/pubmed" id="2685649" target="_blank">2685649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9143857">
<a name="9143857"></a>Young BK, Camicioli R, Ganzini L. Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. <i>Drugs Aging</i>. 1997;10(5):367-383. doi:10.2165/00002512-199710050-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/9143857/pubmed" id="9143857" target="_blank">9143857</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25262534">
<a name="25262534"></a>Zlotnik Y, Giladi N, Hilel A, Shapira Y, Goldstein S, Gurevich T. Levodopa-carbidopa intestinal gel (LCIG) infusion during pregnancy and delivery: first documented case. <i>Parkinsonism Relat Disord</i>. 2014;20(11):1317-1318. doi:10.1016/j.parkreldis.2014.09.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/25262534/pubmed" id="25262534" target="_blank">25262534</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8994 Version 579.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
